Skip to content

Safety and tolerance of oral ketamine: A systematic review.

Nathalia Novaretti, Rebeca Mendes P Pessoa, Jaime Eduardo Cecilio Hallak, Rafael Guimarães Dos Santos, Marcos Hortes N Chagas

Psychiatry and Clinical Neurosciences May 30, 2026 DOI: 10.1111/pcn.70091 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review Randomized Placebo-controlled Peer reviewed
Sample size 427
Population Adults, children, and healthy volunteers
Intervention oral ketamine
Topics Ketamine Esketamine
Keywords Oral administration Adverse effects Safety Tolerability
Key findings Oral ketamine demonstrates a favorable short-term safety profile, though the certainty of evidence is low and long-term safety remains uncertain.

Abstract

Oral ketamine has gained increasing interest beyond anesthesia, particularly for treatment-resistant depression, chronic pain, and pediatric procedural sedation. Despite expanding off-label use, there is no standardized pharmaceutical formulation, and long-term safety remains uncertain. A synthesis of evidence on safety and tolerability of the oral route is therefore needed to inform clinical practice and regulatory development. This systematic review evaluated the safety and tolerability profile of oral ketamine in humans and characterized dosing strategies across randomized controlled trials. A systematic search was conducted in PubMed, Embase, Scopus, and Web of Science from inception to November 2025 (PROSPERO CRD420251065295). Randomized placebo-controlled trials evaluating oral (es)ketamine in any clinical population were included. Primary outcomes were safety and tolerability. Risk of bias was assessed using the RoB2 tool, and certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Eighteen trials were included, comprising adults, children, and healthy volunteers. In depression studies (n = 5; 427 participants), adverse effects were predominantly mild and transient. Pediatric premedication trials (n = 239) reported transient neurological effects without clinically significant safety concerns. Pain and experimental studies (n = 372) showed mostly mild adverse events, with dissociative symptoms at higher doses. Comparative analyses indicated higher rates of dizziness, sedation, and dissociative symptoms with ketamine, while serious adverse events were rare. Overall, oral ketamine demonstrates a favorable short-term safety profile. However, the certainty of evidence is low, and long-term safety remains uncertain.

Comparable studies

Other systematic reviews and meta-analyses on ketamine, most cited first.

Study Year Design Participants
The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis Depressed patients with suicidal ideation at baseline 2017 Systematic review and individual participant data meta-analysis n = 167
Ketamine use: a review Ketamine users 2011 Systematic review
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression Participants with major depression in placebo-controlled, double-blind, randomized... 2015 Systematic review and meta-analysis
Ketamine and postoperative pain – a quantitative systematic review of randomised trials Surgical patients from 25 countries 2004 Systematic review n = 2,839
Side-effects associated with ketamine use in depression: a systematic review. Patients with depression 2018 Systematic review

Citations in the library

Explore topics